Latest Headlines

Latest Headlines

FDA partners with nonprofit device incubator Fogarty Institute to improve approval efficiency

The U.S. Food and Drug Administration and the Fogarty Institute for Innovation, one of the more prominent medical device incubators, have developed a new educational program designed to improve collaboration between medical device innovators and the FDA that's expected to make the device approval process more efficient.

Next-gen infusion pump startup Ivenix nabs $42M to get to market

Infusion pumps are one of the more problematic categories of medical devices with myriad adverse events, including deaths, and recalls associated with the devices. Ivenix expects that its next-gen infusion management system could improve patient safety and workflow efficiency--as well as to adhere to more stringent FDA guidance on infusion systems issued in December.

How openFDA's 'crazy collision' of Silicon Valley and federal culture is reshaping the regulator

Over the past two years the reputation of the IT department at the FDA has changed rapidly. Once best known for burning through CIOs and receiving slapdowns from the congressional watchdog, the FDA is now garnering plaudits for its embrace of agile and open development. This new way of thinking is central to--and to an extent responsible for--the recently unveiled precisionFDA initiative.

Another recall by Indian drugmakers as U.S. FDA notes troubles

Two leading Indian drug firms once again face quality in manufacturing issues with the U.S. FDA, leading in this case to voluntary recalls even as both face extensive remedial actions to bring plants back into the good graces of the regulator.

Insulet says troubled wearable insulin pump plant back on track, just as FDA issues recall notice

Insulet said its long-troubled Billerica, MA, manufacturing plant is back on track on an earnings call earlier this month--just before the FDA offered details on the OmniPod recalls that were caused by inadequate standards compliance. In July, the company issued a voluntary recall of more than 400,000 OmniPod Insulin Management Systems, which are wearable insulin pumps.

Recall roundup: CareFusion infusion pump, J&J sedation device, Teleflex endobronchial tube

The FDA recently deemed corrective actions to three devices as Class 1, reserved for situations in which "there is a reasonable probability that the use of or exposure to a violative product will cause serious adverse health consequences or death."

The FDA offers a controversial solution to the biosimilars name game

The industry has been wrestling for years now over naming the first wave of biosimilars building on the coast of the American drug industry. The FDA's suggested solution: Take the generic name and add four random letters to make it a unique identifier.

The FDA has spoken on biosimilar names. But will its hybrid proposal work?

After much industry lobbying and public debate, the FDA has proposed a system for naming biosimilar drugs. It's a sort of hybrid of the generic name on one hand and the unique brand name on the other. And it would allow the FDA to make some biosims easy to substitute for the brand-name original--and others not so easy.

Woodcock says FDA will keep new plant quality grades a secret

The FDA publishes warning letters and inspection reports on its websites. It issues public recalls and drug label warnings. However, it is not feeling in such a sharing mood when it comes to its proposed letter grades for manufacturing plants on the quality of their manufacturing.

Post-approval interim data on ALS neurostim device confirms survival benefit

When the FDA approved the NeuRx Diaphragm Pacing System to treat chronic hypoventilation in amyotrophic lateral sclerosis (ALS) patients in September 2011 under the Humanitarian Device Exemption (HDE), the agency required an extensive post-marketing study. Now Synapse Biomedical, which markets the neurostimulator breathing device, has reported interim data from that study that's a bit better than the approval data.